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Abstract
Background: We performed a multicenter, open, randomized, clinical study of autologous
cultured osteoblast injection for long-bone fracture, to evaluate the fracture healing acceleration
effect and the safety of autologous cultured osteoblasts.
Methods: Sixty-four patients with long-bone fractures were randomly divided into two groups, i.e.
those who received autologous cultured osteoblast injection and those who received no
treatment. The sum of the difference in the callus formation scores after four and eight weeks, was
used as the first efficacy variable.
Results: The autologous cultured osteoblast injection group showed fracture healing acceleration
of statistical significance, and there were no specific patient complications when using this
treatment.
Conclusion: Autologous cultured osteoblast injection should therefore be considered as a
successful treatment option for treating long-bone fracture.
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During the past few decades, various surgical instruments
and external as well as internal metal fixators have been
developed for the treatment of fractures; these instru-
ments are constantly being improved in order to provide
more effective fracture treatment. To accelerate fracture
healing, ultrasound and other treatment methods have
also recently been introduced[1]. In particular, cell ther-
apy suggests a new treatment approach[2]. For articular
cartilage defects, autologous chondrocyte implantation
has become the major treatment[3], and even as a treat-
ment for fracture, the use of autologous cultured osteob-
lasts has been suggested[4].
When using bone grafts, problems may develop in the
donor area in general autologous bone grafts and immu-
nological problems, while the spread of disease may also
develop in allografts. There may be faster patient recovery
and an absence of these problems when autologous cul-
tured osteoblasts are used[5]. However, as there are only a
small number of cells within bone marrow which can be
differentiated into osteoblasts[6,7], cell culture is essential
for clinical applications. Therefore, it can be anticipated
that osteoblasts obtained using cell culture methods may
be helpful for healing fractures[8].
Kim et al. showed in animal studies that transplanted
autologous cultured osteoblasts induced osteogenesis in
bone defect areas[4]. Our current study was conducted to
determine whether autologous cultured osteoblasts
injected at fracture sites could accelerate the fracture-heal-
ing process.
Methods
Study patients
This was an open clinical trial, and irregardless of patient
gender, among the long-bone shaft (femur, tibia, radius,
ulna, humerus) fracture patients between the ages of 15
and 65 years, our study subjects included 64 patients with
poor callus formation noted approximately six weeks after
surgery (lower than three points on the callus formation
score). Fractures were of the closed type and consisted pri-
marily of simple fractures such as transverse fracture or
oblique fracture.
Patients deemed unsuitable for study participation and
who were therefore excluded included those who were
hypersensitive to bovine protein, hypersensitive to gen-
tamycin, those with acute infection in the transplant area,
patients positive for HIV, HTLV, HCV, HBV or CMV and
on the Syphilis test, pregnant patients, patients who were
nursing or who could be pregnant, and patients diag-
nosed by the investigators to have psychological disor-
ders.
This clinical trial was performed after obtaining permis-
sion from the KFDA (Korean Food and Drug Administra-
tion). Institutional review board approval and informed
consent were obtained from each study patient.
Bone marrow collection and autologous osteoblast culture
From all patients participating in the clinical trial, during
fracture surgery approximately 3 – 5 ml of bone marrow
were collected from the anterosuperior iliac spine and
were added to a container filled with 30 ml of 10% FBS-α
MEM (Sigma Chemical Company, St. Louis, MO, USA)
and 350 units of heparin; the mixture was then taken to
the GMP institution (Sewon Cellontech, Seoul, Korea).
The mixture was centrifuged at 4°C, 472 g for 10 minutes,
after which the supernatant was discarded and 20 ml of
culture medium was added to the remaining pellets. The
mixture was then filtered (Falcon, Franklin Lakes, NJ,
USA), 10 ml of the medium were added per T-75 culture
flask (Corning Science Products, Corning, NY, USA), and
culture was initiated. The incubator (Automatic CO2
Incubator, Forma Scientific Inc, Marietta, OH, USA) was
maintained at 37°C with 5% CO2. The next day, 50 μg L-
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Type I collagen and alkaline phosphatase expression of cultured cells quantified by FACS analysisFigure 2
Type I collagen and alkaline phosphatase expression of cultured cells quantified by FACS analysis.(data not 
shown fully).
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were added to facilitate cell differentiation into osteob-
lasts. The cell culture condition was evaluated using a light
microscope, and the culture medium was changed on the
fifth day of culture, after which the culture medium was
changed every three days with the subsequent addition of
L-ascorbic acid. On the fourteenth day of culture, NBT-
BCIP (nitro blue tetrazolium chloride – 5-bromo-4-
chloro-3-indolyl phosphate) staining was performed to
confirm activation of the alkaline phosphatase(Fig. 1).
Twenty-four days after beginning the culture, Alizarin red
staining was performed to detect newly produced calcium,
and it was thus confirmed that most of the cultured cells
were osteoblasts(Fig. 1).
For flow cytometric analysis, monolayer cells were har-
vested using TrypLE express (Gibco BRL, Gettysburg, PA,
USA) and cell numbers were counted using a hematocy-
tometer. Cells were distributed to each test tube at 1 × 106
and were then resuspended in 50 ul FACS buffer (2% FBS
in PBS). For cell permeabilization, Intraprep Reagent
(Immunotech, Marseille, France) was used, according to
the manufacturer's instructions. Unconjugated, bone-spe-
cific monoclonal antibody, Type I collagen (Abcam, Cam-
bridge, UK), and Bone alkaline phosphatase(Abcam,
Cambridge, UK) were added, and unspecific staining was
determined using isotype controls.
To detect fluorescence, FITC conjugated secondary anti-
body was added to each tube. For analysis, cell pellets
were resuspended in FACS buffer and were then stored at
4°C in the dark and were analyzed by flow cytometry
within the next 2 h(Fig. 2).
Approximately four weeks after beginning the culture, the
medium was removed and the cells were washed with 5
ml 0.02% trypsin-ETDA (Gibco BRL, Gettysburg, PA,
USA). 3 ml of 0.02% trypsin-ETDA was added again, and
the cells were incubated for five minutes. The trypsin-
ETDA activity was stopped by adding 3 ml of culture
medium, and all contents were collected in a conical tube
and were centrifuged at 4°C, 265 g, for six minutes. The
supernatant was removed, and the precipitate was col-
lected. After adjusting the cell count to 1.2 × 107/0.4 ml,
the cells(Ossron™, Sewon Cellontech, Seoul, Korea) were
used in the transplant.
Evaluation of patient suitability for study participation 
(inclusion and exclusion criteria)
This clinical trial was a randomly assigned and open clin-
ical trial designed as a comparative clinical trial and con-
ducted at the Catholic University Hospital, the Young
Dong Severance Hospital, the SangGye Paik Hospital, the
KonYang University Hospital, and the DanKook Univer-
sity Hospital, all located in Korea. If fracture patients vol-
untarily agreed to participate in the study, they were
enrolled according to both the selection and exclusion cri-
teria. The selection criteria were that approximately six
weeks after the first open or closed reduction, the score of
the callus formation was lower than three points, and the
patient agreed to participate in the clinical trial. Many
fractures showed delayed healing when the callus forma-
tion score was lower than three points six weeks after the
fracture surgery, according to the Catholic University Hos-
pital 2004 fracture patient data. The Korean FDA recom-
Method for measuring the callus formation score in the frac-ture areaFigure 3
Method for measuring the callus formation score in 
the fracture area. Slight callus formation is given 1 point. 
b) Bridging callus formation is given 2 points.
Table 1: The method for measuring the callus formation score of the fracture area.
Point(s) anterior cortex posterior cortex medial cortex lateral cortex
0 No callus formation No callus formation No callus formation No callus formation
1 Slight callus formation Slight callus formation Slight callus formation Slight callus formation
2 Bridging callus formation Bridging callus formation Bridging callus formation Bridging callus formationPage 4 of 9
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selection criteria in order to prevent unnecessary osteob-
last injection.
The exclusion criteria applied to patients whose callus for-
mation score was higher than four points, who had posi-
tive results on serum β-HCG testing, who were nursing or
possibly pregnant, and who did not consent to participa-
tion in the clinical trial. The fracture patterns included pri-
marily simple fracture and, if the radiology examiners
were able to evaluate callus formation, also comminuted
fractures.
The experimental and control groups
According to the random assignment table, patients meet-
ing the selection criteria and who were thus enrolled in
the study, were divided into the experimental group into
whom autologous cultured osteoblasts would be trans-
planted and the control group. Approximately eight weeks
after surgery, autologous cultured osteoblasts were
injected into the fracture area of each of the experimental
group patients.
Injection of autologous cultured osteoblasts
Under local anesthesia, each patient was placed on a radi-
ation penetration surgery table; the area to be injected was
sterilized according to the surgery preparation procedure.
The cultured cells prepared in advance were mixed with
fibrin (Greenplast, Green Cross, Korea) at the ratio of 1:1,
placed in a syringe, and a 21-G spinal needle was inserted
into the syringe. The cell number was 1.2 × 107/0.4 ml in
one vial. After five minutes of mixing the cells and fibrin,
the viscosity of the mixture had increased. Using a radia-
tion imaging instrument (C-arm), the cells contained in
the syringe were injected specifically into the fracture area.
Follow-up observation after transplant
During the experiment, the patients carefully followed
their doctors' instructions and, including their hospitali-
zation, they regularly visited a hospital a total of seven
times. To evaluate the safety and efficacy of the osteoblast
injection, the experimental group of patients visited a hos-
pital for two months after the transplant of autologous
cultured osteoblasts, i.e. at one week, one month, and two
months, while the control group visited a hospital at the
same times.
Evaluation methods and statistical analysis
To evaluate the effectiveness of the cultured autologous
osteoblast injection, the modified callus formation
score[9] was used (Fig. 3, Table. 1). No callus formation
in one fracture cortex gave 0 points, slight callus forma-
tion gave 1 point, and bridging callus formation gave 2
points.
The medial and lateral cortices were evaluated on an
anteroposterior radiograph, while the anterior and poste-
rior cortices of the fracture were evaluated on a lateral
radiograph. The callus formation scores of each cortex
were then totaled. Evaluation of the effectiveness, i.e. eval-
uation of the callus formation score, was performed by
two radiologists, neither of whom had performed the
transplant. To obtain the data concerning the effectiveness
of the cultured autologous osteoblast injection, PP (Per-
protocol) analysis was primarily performed, after which
ITT (Intention-to-treat) analysis was used to supplement
the PP analysis. The increased callus formation scores one
and two months after the cell injection, were thus
obtained.
The number of study patients was determined according
to the following conditions. The differences in the callus
formation scores were averaged between the osteoblast
injection time and one month after injection and between
the osteoblast injection time and two months after injec-
tion. The rationale was that the average callus formation
score would differ in both groups. The level of significance
was 0.05, type 2 error was 0.2, distribution was 2.13, and
the difference value was 1.4. The distribution was based
on the data regarding the callus formation score of frac-
ture patients at the Catholic University Hospital. Finally,
The recruitment pathways of the clinical trialFigu e 4
The recruitment pathways of the clinical trial.
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experimental group, anticipating a drop-out rate of 20%.
Therefore, the total number of study patients was 72. As
many patients were dropped from the study, it was very
difficult to accurately determine the exact enrollment
number. During the process of enrolling the study
patients, this factor became inevitable.
Results
This clinical trial began on May 13, 2006 and was closed
on January 16, 2008. The total number of participants was
155, with 77 enrolled patients less the 13 who dropped
out. Therefore, the final total of 64 patients was divided
into an experimental group of 31 patients and a control
group of 33 patients (Fig. 4).
Of the 78 patients who were excluded, 56.4% were
excluded because of a callus formation score greater than
4 points, 12.8% because of their refusal to participate,
20.5% because of positive laboratory findings regarding
infectious disease, and 10.3% for various other reasons.
There were 21 cases of open reduction and internal fixa-
tion (experimental group, 10 cases; control group, 11
cases) and 43 cases of closed reduction and internal fixa-
tion (experimental group, 21 cases; control group, 22
cases).
Among the 72 safety evaluation patients, there were 54
males (75.0%) and 18 females (25.0%). In the experi-
mental group, there were 27 males (77.1%) and eight
females (22.9%), while there were 27 males (73.0%), and
10 females (27.0%) in the control group. The sex differ-
ence between the two groups was not statistically signifi-
cant (p = 0.68) (Table 2).
The average patient age in the total patient group was 39.0
± 13.2 years, while it was 39.5 ± 12.6 years in the experi-
mental group and 38.6 ± 13.8 years in the control group.
The age difference between the two patient groups was not
statistically significant (p = 0.78). There were 25 patients
in their forties (34.7%), 14 (19.4%) in their thirties, and
10 each in their twenties and fifties (13.9%). There was no
age distribution difference between the two groups (p =
0.85) (Table 2).
The average patient height was 168.0 ± 8.1 cm, and the
average weight was 66.4 ± 12.1 kg; there was no statisti-
cally significant difference in either factor between the two
groups (p = 0.82, 0.98) (Table 2). There was no statisti-
Table 3: The fracture distribution in both groups.
Experimental group Control group
humerus 2 1
radius 1 2
ulna 4 2
femur 11 9
tibia 13 18
fibula 0 1
Sum 31 33
Table 2: Demographic data.
Experimental G. Control G Sum p-value
n (%) N (%) n (%)
Sex
male 27 (77.1) 27 (72.3) 54 (75) 0.683
female 8 (22.9) 10 (27.0) 18 (25) χ2-test
mean ± std (year) 39.5 ± 12.6 38.6 ± 13.8 39.0 ± 13.2 0.7833
min~max 16 ~65.00 16 ~64.00 16 ~65.00 t-test
Age
10 ~19 4 (11.4) 5 (13.5) 9 (12.5) 0.8549
20 ~29 4 (11.4) 6 (16.2) 10 (13.9) Exact test
30 ~39 9 (25.7) 5 (13.5) 14 (19.4)
40 ~49 12 (34.3) 13 (35.1) 25 (34.7)
50 ~59 4 (11.4) 6 (16.2) 10 (13.9)
60 ~69 2 (5.7) 2 (5.4) 4 (5.6)
Height n(%) 35 (48.6) 37 (51.4) 72 (100)
mean ± std (cm) 167.7 ± 8.74 168.2 ± 7.55 168.0 ± 8.09 0.817
min~max 151 ~185.00 148 ~190.00 148 ~190.00 t-test
Weight n(%) 35 (48.6) 37 (51.4) 72 (100)
mean ± std (kg) 66.5 ± 13.7 66.4 ± 10.5 66.4 ± 12.1 0.9837
min~max 39 ~110.00 52 ~100.00 39 ~110.00 t-testPage 6 of 9
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between the two groups (p = 0.00) (Table 3).
The average sums of the increased amount of callus for-
mation score in the experimental and control groups at
one and two months following osteoblast injection, were
9.3 and 6.2, respectively, which was statistically signifi-
cant (p = 0.00) (Fig. 5a). On the other hand, the average
callus formation scores at the time of patient enrollment
were 1.4 and 2.1, respectively, in the experimental and
control group patients. The final average callus formation
scores of the experimental and control groups were 7.1
and 5.8, respectively, which was statistically significant (p
= 0.03). But at one month, the data were not statistically
significant (p = 0.196) (Fig. 5b). No side effects caused by
the osteoblast injection were detected during the clinical
trial period.
There was no statistical difference in the osteoblast injec-
tion response between the younger and older age groups.
Also, when we compared the 20–29 year old group with
the other groups, there was no statistical difference (p =
0.71) (Fig. 6).
Adverse events and adverse drug reactions consisted of the
usual postoperative findings after fracture treatment, and
the adverse reaction rate between the two groups was not
statistically different (Table. 4).
There was one MRSA infection in an experimental group
patient, and this infection was treated with antibiotics.
Our IRB determined that this infection had no relation-
ship to this clinical trial.
Discussion
Time has increasingly become the most important factor
in clinical decision-making. Numerous efforts have been
made in various clinical areas to allow trauma patients to
return to their normal life as soon as possible and without
complications[10]. In particular, in patients with frac-
tures, the fractures generally eventually heal, however, in
many patients, bone union can be delayed to an extent
that requires bone transplant. Not only does this cause
psychological and physical pain to the patient, but on a
large scale, it also causes great social loss. The purpose of
our study is to attempt to determine how to reduce this
loss and to assess the possibility of early recovery using
The callus formation scores according to the patient ages of the osteoblast injection groupFigure 6
The callus formation scores according to the patient 
ages of the osteoblast injection group.
a) The sum of the difference in callus formation scores in both groupsFigure 5
a) The sum of the difference in callus formation scores in both groups. b) The callus formation scores in both groups 
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is painful and may have undesirable aftereffects.
With regard to the time required for osteoblast injection,
although it varies depending on the patient for cases with-
out osteogenesis, even two months after bone fracture
injury when the overall bone union rate was evaluated,
the callus formation was relatively slow; in addition, this
is the time period during which the osteogenesis activity
after fracture decreases[11]. Based on the assumption that
irregardless of the type of procedure, if the activity within
a fracture could be increased, the effect of the continuous
callus formation could be maintained and the optimal
time for osteoblast transplant would be approximately
two months after the initial treatment. Following trans-
plant, rapid callus formation could be detected in some of
our control group patients, however, in general, more
rapid and effective callus formation was observed in the
experimental patient group(Fig. 7).
Autologous cultured osteoblast injection is based on bone
marrow injection, the benefit of which is supported by the
theory that osteoprogenitor cells in bone marrow induce
and facilitate bone formation[12]. Bone marrow injection
is performed independently or is combined with a bone
graft procedure. Differing from autologous bone trans-
plant, as bone marrow injection is not a surgical proce-
dure performed by making an incision in the skin in the
donor area, its great advantage is that there are no compli-
cations or adverse side effects. However, as only a limited
amount of bone marrow can be collected from one site,
the number of osteoprogenitor cells contained in the aspi-
rated bone marrow is very limited [13]. Therefore, it has
been proposed that culturing cells and their subsequent
transplantation is the most feasible way to overcome this
limitation[6].
There are several reasons why successful osteogenesis
achieved by injection of autologous cultured osteoblasts,
should be considered, e.g. the procedure is performed by
injection using only a syringe and without any incision
being made, there is only a small amount of tissue injury,
and the procedure does not impair the blood supply.
Because of the surgery required for autologous bone trans-
plant or allogenic bone transplant patients, tissue damage
or impaired blood circulation may occur; osteogenesis or
bone union may also occur because of the resorption
process of transplanted bones. On the other hand, follow-
ing injection, as autologous cultured osteoblasts are con-
nected to adjacent tissue while undergoing formation of
the bone matrix, they do not go through such a process. In
our study, autologous cultured osteoblasts were grafted to
the bone defect area using fibrin as it not only permits
them to safely attach to the defect area but it is also well
The right tibia AP radiographs of a 47-year-old male patient befo e osteoblast injection (a) and eight weeks after injection (b) into h  fracture of the tibi  shaftFigu e 7
The right tibia AP radiographs of a 47-year-old male 
patient before osteoblast injection (a) and eight 
weeks after injection (b) into the fracture of the tibia 
shaft.
a b
Table 4: The adverse events.
Patient number Occurrence number p-value
n (%) N
Adverse Event Exp. 19 (54.3) 42 0.35
Cont. 16 (43.2) 26 χ2-test
Sum 35 (48.6) 68
Adverse Drug Reaction Exp. 9 (25.7) 12 0.19
Cont. 5 (13.5) 8 χ2-test
Sum 14 (19.4) 20
Severe Adverse Event Exp. 1 (2.9) 1 0.49
Cont. 0 (0.0) 0 Exact test
Sum 1 (1.4) 1Page 8 of 9
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known that fibrin, which has been used in surgery for the
purpose of hemostasis, is safe and is readily absorbed
without inducing the reaction caused by foreign material.
In addition, fibrin becomes a vehicle to transport growth
factors in the area where maintenance of the transplant
volume is difficult[14].
The advantages of the technique of autologous cultured
osteoblasts are that, in general, as the initial fracture sur-
gery is performed under general anesthesia, additional
anesthesia is not required for the bone marrow collection.
In addition, as at the time of transplant, cultured osteob-
last injection can be performed under local anesthesia of
the fracture area. Therefore, following the injection,
patients can immediately return to their daily routine and
do not require hospitalization.
For the union of bones, autologous bone transplant is cer-
tainly the most rapid and effective method, however, con-
sidering the pain in the donor area caused by the surgery,
the limited volume of the bone graft, and the additional
surgery required for transplant, we believe that osteoblast
transplant that achieves bone union may be a successful
alternative to autologous bone transplant. In addition, if
such osteoblast transplants could be used for all fracture
patients, not only an early return to their daily routine but
also the prevention of complications following surgery,
such as delayed union and non-union, could also be
anticipated.
Conclusion
Autologous cultured osteoblast transplant is a safe and
effective method for accelerating the rate of fracture heal-
ing.
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